Abstract:Background:B lymphocytes (B cells) are essential in humoral response, and their activation is an important first step for the production of antibodies. However, aberrant B-cell activation is common in the development and progression of autoimmune diseases including systemic lupus erythematosus (SLE), which is characterized by the generation of superfluous autoantibodies. SLE exhibits clinical manifestation such as excessive inflammation and tissue damage. This review aims to summarize the recent emerging studies on aberrant B-cell activation and the associated concurrent therapeutic targets in SLE. Summary:Aberrant B-cell activation is closely associated with the pathogenesis of SLE. Among a variety of mechanisms, dysregulations of B-cell receptor (BCR), toll-like receptor (TLR), and B-cell activating factor receptor (BAFF-R) pathways are the common and dominating factors involved in aberrant B-cell activation. These aberrant signaling transductions play diverse and integrated roles in the development and the pathogenesis of SLE. Therapies targeting aberrant B-cell activation have shown promising efficacy in achieving the clinical alleviation of SLE, suggesting the discovery of new drug targets from these aberrant signaling pathways is imminent. Here, an integrated survey or review of published high-throughput sequencing database covering RNAs of B cells from SLE versus criteria-matched healthy controls highlights that reported signaling molecules in BCR pathway (VAV2, PLC-γ2), TLR pathway (TLR9, P105, IRF7, TAB1), and BAFF-R pathway (SDF-1α) are attitudinally upregulated in SLE patients. This review thus suggests the concurrent and future therapeutic targets and potential biomarkers in both basic and clinical studies of SLE. Key Messages:This review focuses on core B-cell signaling pathways, discussing the progress in the role of aberrant B-cell activation during the pathogenesis of SLE. This review also highlights the signaling molecules from published studies and database for the possible prevention and treatment targets serving the future clinical treatments of SLE.

Up-regulation of proBDNF/p75 NTR signaling in antibody-secreting cells drives systemic lupus erythematosus

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Aberrant CD40-Induced NF-κB Activation in Human Lupus B Lymphocytes

TLR4+CXCR4+ Plasma Cells Drive Nephritis Development in Systemic Lupus Erythematosus

ProBDNF Contributed to Patrolling Monocyte Infiltration and Renal Damage in Systemic Lupus Erythematosus.

Systemic Blockade of Probdnf Inhibited the Expansion and Altered the Transcriptomic Expression in CD3+B220+cells in MRL/lpr Lupus Mice

Human SLE Variant NCF1-R90H Promotes Kidney Damage and Murine Lupus Through Enhanced Tfh2 Responses Induced by Defective Efferocytosis of Macrophages

Peripheral Blood Brain-Derived Neurotrophic Factor Level and Tyrosine Kinase B Expression on T Lymphocytes in Systemic Lupus Erythematosus: Implications for Systemic Involvement

B1-cell-produced anti-phosphatidylserine antibodies contribute to lupus nephritis development via TLR-mediated Syk activation

Aberrant B-Cell Activation in Systemic Lupus Erythematosus.

Involvement of Transcriptional Factor Pbx1 in Peripheral B Cell Homeostasis to Constrain Lupus Autoimmunity

Effect of BDNF on Differentiation of Circulating Th17 and Treg Cells in SLE Patients and Exploration of Signal Transduction Pathways

LSO-002 the Transcriptional Factor Pbx1 Adjusts Peripheral B Cell Homeostasis to Constrain Lupus Autoimmunity

Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway.

Aberrant expansion of follicular helper T cell subsets in patients with systemic lupus erythematosus

THU0380 Increased Expression of Bruton Tyrosine Kinase in Patients with Lupus Nephritis and its Clinic Significance

Treatment with 1,25-Dihydroxyvitamin D3 Delays Choroid Plexus Infiltration and BCSFB Injury in MRL/lpr Mice Coinciding with Activation of the PPARγ/NF-κB/TNF-α Pathway and Suppression of TGF-β/Smad Signaling

Excessive activation of the TLR9/TGF-β1/PDGF-B pathway in the peripheral blood of patients with systemic lupus erythematosus

Increased Expression Of Bruton Tyrosine Kinase In Patients With Lupus Nephritis And Its Clinic Significance

A Novel Epitope From Cd22 Regulates Th1 And Th17 Cell Function In Systemic Lupus Erythematosus

Sphingomyelin Synthase 1 Enhances BCR Signaling to Promote Lupus-Like Autoimmune Response.